US-based Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Germnay-based Bayer AG, announced on Thursday that it has named Gustavo Pesquin as its new chief executive officer (CEO) effective 11 March 2023.
Pesquin has served as chief commercial officer at Amneal Pharmaceuticals, Inc. He has over 10 years of experience at Sanofi, where he served in leadership roles of increasing responsibility, including North America head for General Medicines and global head of the Diabetes and Cardiovascular Franchise. He has held the position of regional head, general manager, sales head and strategy head roles at Abbott and Pfizer; brand management roles at Procter & Gamble; and consultant roles with Boston Consulting Group.
Pesquin holds an MBA with a concentration in Management and Strategy, Finance and Accounting from Kellogg School of Management at Northwestern University and a bachelor's degree in Public and Business Administration from Universidad Nacional de Cuyo in Argentina.
GSK wins European Commission approval for Shingrix prefilled syringe
Tri-City Cardiology adds new members to care team
GENinCode expands Mexico presence with CARDIO inCode-Score distribution agreement
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
InsiteOne agrees strategic partnerships with ASCEND Cardiovascular and Apollo Enterprise Imaging
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Remington Medical's VascuChek 2.0 Cordless Bluetooth-Enabled Doppler Secures FDA Clearance
LivaNova secures higher Medicare reimbursement for VNS Therapy procedures